Monitoring of oxygen delivery and tissue oxygenation deprivation in critically ILL neonates using resonance raman spectroscopy
Ended Project Grant Awarded Last action
- Award ID
- R43HD116647
- Recipient
-
Pendar Technologies LLC UEI EVJWXL9HAYN5
- Awarding agency
-
National Institute of Child Health and Human Development
National Institutes of Health, Department of Health and Human Services
- Obligated
- $318,724
Award facts
- Assistance listing
- 93.865 Child Health and Human Development Extramural Research
- Completion date
- Place of performance
- Massachusetts, USA
Award details come from USAspending.gov.
Description
- Abstract
- Shock physiology, from any cause, is characterized by an inability to deliver sufficient oxygen to the tissues to meet cellular metabolic demands. Unfortunately, tools that assess the adequacy of oxygen delivery in neonatal critical care patients are often invasive, imprecise, intermittent, and may be misleading. For example, a patient with significant microvascular shunting may exhibit a falsely reassuring arterial oxyhemoglobin saturation or normal lactic acid levels. Still, early identification of the shock state is critical to the appropriate triage, resuscitation, and treatment of patients. Here, we propose the advanced development and testing of an optical probe that monitors peripheral tissue oxygenation as a marker of systemic hemodynamics with strong correlation to central venous oxygen saturation. Local, capillary-SHBO2 (called STO2), primarily reflects the venous or post-O2 extraction compartment of the vasculature and, thus, reflects the adequacy of oxygen delivery to tissues. Changes to systemic blood supply, for example due to bleeding, infection, or low cardiac output may not change arterial oxygen saturation, but are quickly reflected in peripheral STO2 as total oxygen delivery is reduced or peripheral capillaries are shunted to maintain systemic perfusion. We have developed a method for measuring STO2 based on resonance raman spectroscopy (RRS). RRS takes advantage of resonant enhancement of the vibrational spectra from hemoglobin when excited using a low power laser near a strong absorption peak (405NM). Thus, the STO2 measurement can be taken against a tissue background and is insensitive to factors such as subcutaneous FAT and skin color. Using a prototype device in animal models, we have demonstrated the utility and feasibility of measuring STO2 from the esophagus as a predictor of decompensation due to hemorrhage. In addition, we confirmed the safety of long term use of the device. Here, we propose improvements to our sensor which will enable measurements in a wider range of tissues and will prepare US to begin clinical trials in a neonatal critical care patient population.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Original award | $318,724 |
Quick answers
Who received award R43HD116647?
R43HD116647 was awarded to Pendar Technologies LLC by National Institute of Child Health and Human Development (National Institutes of Health) on September 1, 2024.
How much is award R43HD116647 worth?
$318,724 has been obligated on R43HD116647.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award